Evaluate the clinical efficacy of Osimertinib in patient with metastatic EGFR-mutant (EGFRm+) NSCLC after prior first-line TKI therapy.
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.